KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Net Margin (2016 - 2025)

Emergent BioSolutions' Net Margin history spans 14 years, with the latest figure at 36.72% for Q4 2025.

  • For Q4 2025, Net Margin fell 2064.0% year-over-year to 36.72%; the TTM value through Dec 2025 reached 7.08%, up 2980.0%, while the annual FY2025 figure was 7.08%, 2534.0% up from the prior year.
  • Net Margin reached 36.72% in Q4 2025 per EBS's latest filing, down from 22.15% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 39.07% in Q3 2024 to a low of 566.2% in Q2 2024.
  • Average Net Margin over 5 years is 44.36%, with a median of 13.75% recorded in 2021.
  • Peak YoY movement for Net Margin: crashed -48884bps in 2024, then soared 55768bps in 2025.
  • A 5-year view of Net Margin shows it stood at 24.27% in 2021, then tumbled by -184bps to 20.29% in 2022, then increased by 12bps to 17.9% in 2023, then grew by 10bps to 16.08% in 2024, then plummeted by -128bps to 36.72% in 2025.
  • Per Business Quant, the three most recent readings for EBS's Net Margin are 36.72% (Q4 2025), 22.15% (Q3 2025), and 8.52% (Q2 2025).